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Pardiac-Directed Expression of Adenylyl Cyclase VI
acilitates Atrioventricular Nodal Conduction
shwani Sastry, BS,* Elizabeth Arnold, BA,* Hunaid Gurji, BS,*† Atsushi Iwasa, MD,*†
anh Bui, MD,*† Alborz Hassankhani, MD, PHD,*† Hemal H. Patel, PHD,* James R. Feramisco, PHD,*
avid M. Roth, MD,*† N. Chin Lai, PHD,† H. Kirk Hammond, MD,*† Sanjiv M. Narayan, MB, MD*†
an Diego, California
OBJECTIVES The purpose of this study was to test the hypothesis that cardiac-directed expression of
adenylyl cyclase VI (ACVI) facilitates atrioventricular (AV) nodal conduction.
BACKGROUND Cardiac-directed expression of ACVI, unlike other strategies to increase cyclic adenosine
monophosphate generation, reduces mortality in murine cardiomyopathy. Recent reports
suggest that ACVI expression may also protect against lethal bradycardia.
METHODS We performed immunofluorescence staining for ACVI in the AV node of transgenic mice.
We then performed electrophysiologic studies (EPSs) using a 1.7-F octapolar catheter at the
AV junction in 11 transgenic ACVI mice and 14 control mice.
RESULTS Immunofluorescence staining revealed increased ACVI expression in the AV node of
transgenic mice versus controls. During EPS, AV intervals approximated PR intervals (R2 
0.99) and related linearly to atrial-to-His intervals (R2  0.98; both p  0.0001). Thus, we
studied AV intervals to avoid electrocardiogram pacing artifacts and inconsistent inscription
of His bundle electrograms. At baseline, ACVI mice had shorter AV intervals (47  9 ms)
than controls (57 11 ms; p 0.02), despite similar sinus rates. In pacing, AV intervals were
shorter in ACVI mice than controls for a wide cycle-length range (p 0.01). The ACVI mice
also had shorter AV Wenckebach cycle lengths (ACVI: 114  12 ms; control: 131  28 ms;
p 0.05) and ventriculo-atrial effective refractory periods (ACVI: 97 21 ms; control: 127
15 ms; p  0.05). We observed no differences between groups in sinus node function, and
ventricular arrhythmias were not inducible.
CONCLUSIONS Cardiac-directed expression of ACVI facilitates AV nodal conduction without altering sinus
node function. These results suggest the need to define a role for ACVI gene transfer in
treating diseases of AV conduction. (J Am Coll Cardiol 2006;48:559–65) © 2006 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.01.082American College of Cardiology Foundation
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mongestive heart failure (CHF) affects more than 5 million
eople in the U.S. and is a significant cause of morbidity and
ortality. Clinically, inhibition of the renin-angiotensin-
ldosterone system (1) or antagonism of beta-adrenergic
eceptors (ARs) (2,3) reduces the mortality and morbidity
f CHF. Conversely, pharmacological agents that increase
ntracellular levels of cyclic adenosine monophosphate
cAMP) typically shorten life (4), despite favorable effects
n left ventricular function and symptoms. These observa-
ions are mirrored in animal studies, in which cardiac-
irected AR and Gs expression initially increase cardiac
ontractile function but are ultimately associated with
dverse outcomes (5–7).
Cardiac-directed expression of adenylyl cyclase type VI
ACVI), in contrast, is emerging as a useful strategy to
ncrease contractile function while avoiding deleterious
ffects usually associated with agents that increase intracel-
ular cAMP (8–10). Adenylyl cyclase type VI, a major
From the *University of California, San Diego, California; and the †Veterans
ffairs San Diego Healthcare System, San Diego, California. This work was
upported by National Institutes of Health Summer Fellowship awards (to Mr. Sastry
nd Ms. Arnold), an ACC-Merck award (to Dr. Bui), Merit Awards from the
epartment of Veterans Affairs (to Drs. Roth and Hammond), NIH 1 P01 HL66941
to Drs. Hammond and Feramisco), NIH R01 HL080741 (to Dr. Hammond), and
merican Heart Association Grant-In-Aid (0265120Y) (to Dr. Narayan).s
Manuscript received August 1, 2005; revised manuscript received December 12,
005, accepted January 5, 2006.ardiac isoform of AC, increases cAMP generation after
AR stimulation without increasing basal cAMP. In mu-
ine cardiomyopathy (10) and pacing-induced porcine heart
ailure (11), increased cardiac ACVI improves cardiac func-
ion (9–11) and reduces mortality (10). Clinical trials to
tudy the benefits of ACVI gene transfer in patients with
evere CHF will commence shortly.
However, the electrophysiologic effects of increased
ardiac ACVI expression are unknown. In particular,
lthough ACVI is expressed in the sinus node (12), its
xpression and functional importance in the atrioventric-
lar (AV) node are unclear. Studies from our laboratory
how that ACVI mice are protected against AV nodal
lock after coronary artery ligation (13), although the
echanism is unknown. In addition, while ACVI expres-
ion enhances sinus node chronotropy (8), it is unclear to
hat extent cardiac ACVI expression, like other adrener-
ic interventions, pre-disposes to atrial or ventricular
rrhythmias.
In the present study, we confirmed the expression of
CVI in the AV node of transgenic mice, and then tested
he hypothesis that cardiac-directed ACVI expression facil-
tates AV nodal conduction. Furthermore, we performed
etailed invasive electrophysiologic studies (EPSs) to deter-
ine whether increased cardiac ACVI expression increasesusceptibility to atrial or ventricular arrhythmias.
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nimals. The study protocol was approved by the Animal
are Program of the San Diego Veterans Affairs Medical
enter, and we maintained humane treatment of all study
ubjects. Transgenic mice with cardiac-directed ACVI ex-
ression (n  20; mean age 11 months) were generated
sing the major histocompatibility complex (MHC) pro-
oter as previously described (8). Transgene-negative sib-
ings (n  5) and wild-type mice of the same strain
C57BL/6; n  14) were used as controls (mean age 8
onths). We could not obtain data on 14 of these 39 mice:
1 died during surgical preparation before EPS (7 ACVI,
Abbreviations and Acronyms
ACVI  adenylyl cyclase type VI
AH  atrial-to-His
ANOVA  analysis of variance
AV  atrioventricular
AVERP  atrioventricular nodal effective refractory
period
AR  beta-adrenergic receptor
cAMP  cyclic adenosine monophosphate
CHF  congestive heart failure
CL  cycle length
CSNRT  corrected sinus node recovery time
ECG  electrocardiogram
EPS  electrophysiologic study
ERP  effective refractory period
MHC  major histocompatibility complex
SNRT  sinus node recovery time
VA  ventriculo-atrial
igure 1. Surgical field and electrophysiology catheter. (A) View of right e
ouse. (B) Close-up of venous cutdown with proximal and distal sutures. The
he atrioventricular junction and then sutured in place.control), and we could not obtain suitable catheter
osition in 3 (2 ACVI, 1 control). This report is based on
ata from the remaining 25 mice.
urgery. Mice were anesthetized with intraperitoneal
njections of ketamine (100 mg/kg) and xylazine (5 mg/kg)
14) and received 100% oxygen (1 l/min) via nose cone.
ice were placed on their dorsa on a heating pad main-
ained at 37°C, and surface electrocardiogram (ECG) leads
ere recorded from electrodes on each limb; ECG and
espiratory rate were monitored throughout the procedure.
ransvenous electrode placement. A 10- to 15-mm lon-
itudinal paratracheal incision was made at the level of the
arynx. Blunt dissection aided by an operating microscope
as used to expose the right external jugular vein. Mi-
roscissors were used to create a venotomy, and a 1.7-F
ctapolar pace/sense catheter (Numed Inc., Hopkinton,
ew York) was carefully advanced to the AV junction such
hat right atrial and ventricular electrograms were observed
n proximal and distal bipoles, respectively. Figure 1 shows
he surgical field, external jugular vein, and catheter. Elec-
rogram recordings were optimized by adjusting the catheter
osition and signal gain, and then the catheter was sutured
n place.
rogrammed stimulation. Intracardiac electrograms and
he surface ECG were filtered between 5 and 500 Hz and
0 and 100 Hz, respectively, and analyzed at a scale of 200
m/s from our physiologic recorder (Labsystem Duo, Bard,
assachusetts). Atrial and ventricular pacing were per-
ormed using 1-ms pulse widths at twice diastolic threshold,
nd each maneuver was performed twice.
l jugular cutdown and 1.7-F electrophysiology catheter in an anesthetizedxterna
venotomy is made between these sutures, and the catheter is advanced to
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August 1, 2006:559–65 Adenylyl Cyclase and AV Nodal ConductionSinus node recovery time (SNRT) was measured as the
eturn atrial cycle length (CL) after 30 s of overdrive atrial
acing at CL 150 ms, or 10 to 20 ms less than sinus CL,
hichever was shorter. Corrected sinus node recovery time
CSNRT) was obtained by subtracting the pre-pacing sinus
L (mean of 5 cycles) from SNRT. Atrioventricular inter-
als closely approximated PR intervals at a variety of CLs
linear regression: slope  0.99, intercept  0.50 ms; R2 
.99, p  0.0001). Thus, we studied AV intervals, because
CG P waves were often obscured by artifacts during atrial
acing. Since the inscription of His bundle electrograms
as inconsistent during stimulation, as is often seen in mice
14,15), AV intervals were also used as surrogates for
trial-to-His (AH) intervals. We validated this surrogate
14,16) via the linear relationship of AV to AH intervals at
ll CLs when both were measurable (R2  0.98; slope 
.90; p  0.0001).
Incremental atrial pacing was performed to determine the
V interval–CL relationship, AV Wenckebach, and 2:1 AV
lock CLs. Atrioventricular nodal effective refractory period
AVERP) and atrial effective refractory period were deter-
ined using 15-beat atrial drive-train stimuli (S1) at CL
50 ms followed by progressively earlier extrastimuli (S2).
nduction of atrial arrhythmias was attempted using double
nd triple extrastimuli, coupled progressively earlier until
oss of capture, and then burst atrial pacing.
Programmed ventricular stimulation commenced with
urst pacing to determine ventriculo-atrial (VA) conduc-
ion, Wenckebach, and 2:1 block CL. Effective refractory
eriod was determined for ventricular and VA conduction
when present) using 15 beats of drive train (S1) stimulation
t CL 150 ms and progressively earlier S2. Ventricular
rrhythmia induction was attempted with up to 6 extra-
timuli (S2 to S7), each coupled more prematurely until loss
f capture, followed by burst ventricular pacing to CL 50
s. Induced ventricular arrhythmias were defined as 3 or
ore repetitive ventricular responses.
Finally, intraobserver and interobserver reproducibility
ere assessed. For PR, AV, and AH intervals, Pearson
oefficients for interobserver measurements (AS, SMN)
ere r  0.98, 0.97, and 0.98, respectively (p  0.0001 for
ach), with no difference between means. For intraobserver
R, AV, and AH interval measurements, Pearson coeffi-
ients were 0.99, 0.98, and 0.98, respectively (p  0.0001
or each), with no difference between means.
At the conclusion of the experiment, mice were killed
sing an overdose of ketamine and xylazine.
CVI expression in AV node. Fresh frozen sections (10
m) of hearts obtained from mice with cardiac-directed
CVI expression and transgene-negative siblings were fixed
n 100% methanol for 10 min at20°C. Fixed sections were
locked in 1% bovine serum albumin for 20 min and
ncubated with Cx45 mouse monoclonal primary antibodies
Chemicon Inc., Temecula, California) to stain AV nodal
issue, and ACV/ACVI rabbit polyclonal antibodies (Santa
ruz Biotechnology, Inc., Santa Cruz, California) at 1:100 Ailution for 24 h at 4°C. After primary incubation, sections
ere washed in TBS-Tween (0.1%, 3X, 5 min) and incu-
ated with FITC and rhodamine-conjugated secondary
ntibodies (Molecular Probes, Inc., Eugene, Oregon) for
h. The sections were washed again in TBS-Tween (0.1%,
X, 5 min) to remove non-specific binding and incubated
ith DAPI (1:5000) to stain nuclei. Stained sections were
ounted with gelvatol on glass coverslips and allowed to dry
or 24 h before imaging. Images were captured with a
eltaVision deconvolution epifluorescence microscope sys-
em (Applied Precision, Inc., Issaquah, Washington). Ten
ptical sections spaced by 0.2 m were taken at 10 or 60
agnification. Exposure times were set such that the camera
esponse was in the linear range for each fluorophore and
tandardized for all images.
tatistical analysis. Two-tailed unequal variance t tests
ere used to compare data between ACVI and control
roups, and repeated measures analysis of variance
ANOVA) was used to detect group differences in AV
onduction at various CLs. Pearson coefficient was used to
ssess interobserver and intraobserver variability in AH,
V, and PR intervals, with t tests to assess differences
etween the means. Chi-square analysis was used to com-
are the presence or absence of retrograde VA conduction
etween groups. The null hypothesis was rejected when
 0.05.
ESULTS
ontrol mice. In this study, we used 2 groups of control
ice: 5 transgene-negative siblings, and 9 wild-type mice of
he same strain. Statistical testing between these 2 groups
f control mice revealed no differences in any measure of
lectrophysiologic function. Therefore, these groups were
ombined into a single group (n  14) and compared to the
CVI transgene-positive animals (n  9).
V and VA conduction. At baseline, the AV interval was
horter in ACVI mice (ACVI: 47  9 ms; control: 57  11
s; p  0.02), despite similar baseline sinus CL (Table 1).
lthough His bundle electrograms were obtained in many
ice, they were visible throughout the entire protocol in
nly a subset (for example, Fig. 2). However, when intra-
ardiac AV and AH intervals were both observed, they
orrelated linearly (p  0.0001), excluding significant inde-
endent effects from His-ventricular (HV) interval changes
n either group.
On atrial pacing (Table 1), AV intervals were shorter in
CVI than in control mice (p  0.01, ANOVA) (Fig. 3).
he AV Wenckebach CL (Fig. 4) was shorter in ACVI mice
ACVI: 114  12 ms; control: 131  28 ms; p  0.05), as
as the longest AV interval before the non-conducted
-wave (ACVI: 96  10 ms; control: 109  20 ms; p 
.05). The AV 2:1 block CL (ACVI: 96  11 ms; control:
13  25 ms; p  0.07) and AVERP (ACVI: 81  26 ms;
ontrol: 98  32 ms; p  0.17) trended to be shorter in
CVI mice.
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Adenylyl Cyclase and AV Nodal Conduction August 1, 2006:559–65On ventricular pacing, ACVI mice trended toward exhib-
ting VA conduction more often than controls (p  0.08).
n mice showing VA conduction, VA effective refractory
eriod (ERP) was shorter in ACVI mice (ACVI: 97  21
s; control: 127  15 ms; p  0.05), and VA Wenckebach
L trended to be shorter (ACVI: 136 21 ms; control: 166
7 ms; p  0.07).
ther measurements. No group differences were seen in
NRT (ACVI: 383  159 ms; control: 420  162 ms; p 
.57) or CSNRT (ACVI: 163 153 ms; control: 218 132
s; p  0.35), nor in atrial or ventricular ERP.
able 1. Electrophysiologic Measurements
ACVI
(n  11)
Control
(n  14) p Value
aseline measurements
Sinus CL (ms) 235  77 208  70 0.38
Range in sinus CL (ms) 183  120 166  78 0.69
Baseline AV interval (ms) 47  9 57  11 0.02
trial pacing
SNRT (ms) 383  159 420  162 0.57
(C)SNRT (ms) 163  153 218  132 0.35
A ERP (ms) 64  20 70  15 0.51
AV Wenckebach CL (ms) 114  12 131  28 0.05
AV 2:1 CL (ms) 96  11 113  25 0.07
Longest AV interval (ms) 96  10 109  20 0.05
AV ERP (ms) 81  26 98  32 0.17
entricular pacing
VA Wenckebach CL (ms) 136  21 166  27 0.07
VA ERP (ms) 97  21 127  15 0.05
V ERP (ms) 70  29 70  10 0.9
 atrium; ACVI  adenylyl cyclase type VI; AV  atrioventricular; CL  cycle
ength; (C)SNRT  (corrected) sinus node recovery time; ERP  effective refractory
eriod; V  ventricular; VA  ventriculo-atrial.
igure 2. Electrocardiogram and intracardiac electrograms during sinus rhy
t the atrioventricular junction. Bipoles are labeled Intra-P (proximal, atrial), Intr
entricular), respectively. Scale markings are in ms and intervals are marked. Arrhythmias. Two mice, 1 control mouse (age 4 months),
nd 1 ACVI mouse (age 5.5 months) exhibited spontaneous
on-sustained (30 s) accelerated junctional rhythm (Fig.
A). One control mouse developed a single episode of atrial
achycardia of CL 36 ms and duration 600 ms (Fig. 5B),
ikely induced by atrial pacing within the vulnerable period
f the preceding P-wave (labeled), with accelerated and
ariable ventricular rate (4:1 and 5:1 AV conduction).
ermination was either spontaneous or related to the next
trial pacing stimulus. The tachycardia mechanism could
ot be elaborated on further because this finding was not
eproduced. Ventricular tachycardia (3 beats) could not be
nduced in any animal despite aggressive stimulation.
CVI expression in AV node. To determine whether in-
reased AV conduction was a direct consequence of increased
howing atrial, His, and ventricular electrograms from an octapolar catheter
igure 3. Atrioventricular (AV) conduction and cycle length. Atrioven-
ricular intervals were shorter in adenylyl cyclase type VI (ACVI) mice than
n controls for a range of cycle lengths. The p value from analysis of
ariance; mean values  1 SEM are shown.thm, s
a-3 (atrioventricular junction), Intra-2 (His position), and Intra-D (distal,
H  atrial-to-His; HV  His-to-ventricular.
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August 1, 2006:559–65 Adenylyl Cyclase and AV Nodal ConductionCVI expression in AV nodal tissue, rather than an indirect
e.g., reflex-mediated) effect, we used immunodetection with
V node-specific and AC-specific antibodies. Increased
igure 4. Atrioventricular nodal Wenckebach during atrial pacing at cycle
ipoles and timescale are labeled as in Figure 2.
igure 5. (A) Transient accelerated junctional rhythm. Episodes were of
hort duration (lasting seconds), self-limited, and seen in 1 animal from
ach group. (B) Transient atrial tachycardia. This rhythm was observed in
control-group mouse (cycle length 36 ms), likely induced by atrial pacing
ithin the vulnerable period of the preceding native P-wave (labeled *).
ote accelerated and variable ventricular rate during tachycardia. This
nding was not reproduced and was seen only in this mouse. Bipoles and
imescale are labeled as in Figure 2.xpression of ACVIin the AV node was shown by immu-
ofluorescence staining in regions that also demonstrated
onnexin 45 staining (denoting AV node). The ACVI
xpression was increased in the AV node and myocardium
f transgene-positive versus -negative mice (Fig. 6C).
ISCUSSION
his is the first study to demonstrate that AV nodal
onduction is facilitated by cardiac-directed expression of
CVI via the MHC promoter, and the first to provide
mmunohistochemical confirmation of AV nodal expression
f ACVI. At EPS, AV nodal conduction was facilitated in
ransgenic mice at baseline, during constant-rate pacing,
nd after premature extrastimuli. In contrast, ACVI expres-
ion conferred no clear phenotype in sinus nodal function,
or in atrial or ventricular refractory periods, despite known
xpression in these tissues. Cardiac-directed ACVI expres-
ion has already been shown to increase inotropic response
o catecholamines in normal (8) and cardiomyopathic (9)
ice, and in normal (17) and cardiomyopathic pigs (11).
he current study suggests the intriguing possibility that
ardiac-directed ACVI expression may have a role in treating
isorders of AV conduction or attenuating the negative
romotropic effects of AR antagonists in individuals with
eart failure.
trioventricular nodal function. Not only did ACVI mice
xhibit increased antegrade AV conduction (shorter AV
ntervals, AV Wenckebach, and 2:1 block CL), but retro-
rade VA conduction was correspondingly enhanced. These
ffects are consistent with the expected effects of increased
th 120 ms, showing atrial-to-His (AH) Wenckebach (intervals marked).AR signaling on the AV node, and they suggest that ACVI
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Adenylyl Cyclase and AV Nodal Conduction August 1, 2006:559–65xpression facilitates AR signaling at baseline as well as
uring stimulation.
inus nodal function. This study confirms previous results
hat ACVI expression does not alter baseline sinus CL or
eart rate variability (18) (Table 1).
The apparent selectivity of the ACVI phenotype for the
V node rather than the sinoatrial node is intriguing. We
ave previously shown widespread ACVI expression in
ardiac tissues of transgenic mice, including the sinoatrial
ode (12), and the present study is the first to confirm
xpression in the AV node. First, phenotypic differences
ay reflect the influences of autonomic innervation in each
egion, in that baseline vagal tone may influence the sinus
ode (and attenuate its ACVI phenotype in transgene-
igure 6. Expression of ACVI in AV node. (A) 10 images of AV node
ndicates staining for Cx45, a marker for AV nodal tissue; red indicates AC
B) 60 images of area contained in white box in (A). There is considerabl
nd transgene-negative sibling mouse (control); heart sections exposed to
rom transgene-negative sibling. White bar lengths are (A) 100 m; (B)ositive mice) to a greater extent than the AV node. aotably, we recently demonstrated, using telemetry and
harmacological interventions, that sinus rate variability
and hence autonomic tone per se [19]) is unaltered in ACVI
ersus control animals (18). Second, apparent selectivity
ay be a consequence of differing effects of anesthesia on
he sinus versus AV nodes. Finally, SNRT and CSNRT
ay provide only limited information on the sinus nodal
henotype of ACVI expression, and alternative indices
ncluding chronotropic reserve may be required to fully
haracterize sinus nodal function.
TRIAL AND VENTRICULAR ARRHYTHMIAS. Although
ardiac-directed ACVI expression increases AR respon-
iveness (1,12,18), our results suggest that it is not pro-
in heart from a mouse with cardiac-directed expression of ACVI. Green
rotein; overlap image (right) indicates co-expression of Cx45 and ACV/VI.
ocalization of Cx45 AV nodal stain with ACV/VI. (C) 60 image of ACVI
VI antibodies show increased ACVI expression compared to heart sections
; (C) 20 m. Abbreviations as in Figures 2 and 3.region
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hythm, once in a control animal and once in an ACVI
ouse. The 1 transient (1 s) episode of atrial tachycardia
as observed in a control animal.
Similarly, ACVI expression did not increase susceptibility to
entricular tachycardia or ventricular fibrillation in these mice,
nlike traditional sympathomimetic interventions (20). This
as true despite very aggressive ventricular stimulation proto-
ols that have been shown to induce ventricular arrhythmias in
ice with structural heart disease (15,21). We also found no
ifferences in ventricular refractory periods in ACVI versus
ontrol mice. Indirectly, these results also support our prior
tudies that cardiac-directed ACVI expression is not associated
ith abnormalities in cardiac structure (8).
linical implications. These results suggest a mechanism
y which cardiac-directed ACVI expression may prevent
orbidity or mortality from AV block, with or without
o-treatment with AR antagonists, in patients with heart
ailure. Indeed, in a study of mice with implanted telemetry
evices, we found that ACVI mice were protected against
radycardic mortality after ligation of the left coronary
rtery when compared to control mice (13).
tudy limitations. Difficulties in consistently recording
is-bundle electrograms in mice for prolonged periods have
een noted in epicardial (14) as well as endocardial (15)
ecordings. However, our use of AV intervals as previously
eported surrogates for the AH interval (15,16,21) was
upported by a strong linear correlation between AH and
V intervals. We used endocardial recordings to reduce
otential autonomic (and thus electrophysiologic) changes
rom the surgery and pain involved with epicardial electrodes.
Theoretically, an important limitation of attempted ar-
hythmia induction is that these protocols are honed for
umans (20), with unproven efficacy in mice. Nonetheless,
uch protocols have been used to induce arrhythmias in mice
ith various structural heart diseases (15,21). Finally, al-
hough differences in sedation between mice are a potential
onfounding factor, differences should apply equally be-
ween groups, and our protocols were also similar to
reviously described murine sedation schemes (16).
Finally, the use of transgenic mice limits extrapolation of our
esults to ACVI gene therapy for AV nodal disease in CHF. In
ddition, further studies should explore how AV nodal facili-
ation would interact with the high sympathetic tone of CHF,
r whether shortening of anterograde block CL would elevate
entricular rate in CHF-associated atrial fibrillation.
onclusions. Electrophysiologic testing showed that
ardiac-directed expression of ACVI enhances anterograde
nd retrograde conduction through the AV node at baseline
nd during pacing, without affecting basal sinus rate or sinus
ode function, or inducing pro-arrhythmia. Immunofluo-
escence confirmed that cardiac-directed expression of ACVI
nvolved the AV node. We speculate that gene transfer of
CVI to the AV node may be useful to ameliorate the negative
romotropic effects of AR antagonists in patients with
eart failure. This presupposes that the levels of expressionbtained by gene transfer would be adequate to have such an
ffect and would require additional studies.
eprint requests and correspondence: Dr. Sanjiv M. Narayan,
irector of Electrophysiology, VA Medical Center, Co-Director,
lectrophysiology Training Program, University of California, San
iego, Cardiology 111A, 3350 La Jolla Village Drive, San Diego,
alifornia 92161. E-mail: snarayan@ucsd.edu.
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